IL17A and systemic lupus erythematosus: IL-2 treatment alters the cytokine environment by decreasing the production of pro-inflammatory cytokines such as interferon (IFN)-γ, IL-17, and tumor necrosis factor (TNF)-α, which are increased in SLE [17].